Skip to content
Pharma Observatory a Scientist.com platform
  • Trial site

Trial site location from the registry's own city and country. GeoNames (geonames.org).

Clinical trial site

MD Anderson Cancer Center

MD Anderson Cancer Center in Houston, Texas, United States is listed as a site for 1,533 registered clinical trials, 632 of them ongoing.

Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Registered trials 1,533
Ongoing 632

This page covers the site record MD Anderson Cancer Center in Houston, Texas, United States: the trials that list it by this name in ClinicalTrials.gov. The same place can be registered under other names, each with its own page and its own trials, and a count here is a number of registered trials, not of patients enrolled.

Get the MD Anderson Cancer Center report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Trials by phase

Registered trials that list this site, by trial phase. 1,533 trials counted.

  • Phase 1 446 trials
  • Phase 1/2 291 trials
  • Phase 2 391 trials
  • Phase 2/3 16 trials
  • Phase 3 139 trials
  • Phase 4 13 trials
  • Not applicable 91 trials
  • Observational 133 trials
  • Expanded access 13 trials

Trials by status

The registry's own status summary: Ongoing, Completed, Terminated or Other.

  • Ongoing 638 trials
  • Completed 521 trials
  • Terminated 310 trials
  • Other 64 trials

Trials over time

Trials registered with a start date in each year, 1990 onward, most recent years first.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 169

1996: 1 trials (Not applicable 1) 1998: 1 trials (Observational 1) 1999: 3 trials (Observational 1, Not applicable 1, Phase 2 1) 2000: 3 trials (Phase 2 1, Phase 1/2 2) 2001: 13 trials (Not applicable 2, Phase 3 2, Phase 2 4, Phase 1/2 3, Phase 1 2) 2002: 16 trials (Phase 3 4, Phase 2/3 1, Phase 2 5, Phase 1/2 5, Phase 1 1) 2003: 22 trials (Observational 1, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 12, Phase 1/2 4, Phase 1 2) 2004: 16 trials (Not applicable 1, Phase 4 1, Phase 3 2, Phase 2 9, Phase 1/2 2, Phase 1 1) 2005: 24 trials (Observational 1, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 6, Phase 1/2 5, Phase 1 6) 2006: 23 trials (Observational 1, Phase 3 6, Phase 2 13, Phase 1/2 1, Phase 1 2) 2007: 32 trials (Observational 2, Not applicable 1, Phase 3 3, Phase 2 8, Phase 1/2 4, Phase 1 14) 2008: 19 trials (Observational 2, Phase 3 1, Phase 2 9, Phase 1/2 4, Phase 1 3) 2009: 28 trials (Observational 4, Not applicable 3, Phase 4 1, Phase 3 2, Phase 2 11, Phase 1/2 2, Phase 1 5) 2010: 34 trials (Observational 4, Not applicable 1, Phase 4 1, Phase 3 4, Phase 2 12, Phase 1/2 5, Phase 1 7) 2011: 32 trials (Observational 5, Phase 3 2, Phase 2 12, Phase 1/2 5, Phase 1 8) 2012: 31 trials (Observational 3, Not applicable 2, Phase 3 2, Phase 2 8, Phase 1/2 5, Phase 1 11) 2013: 36 trials (Observational 4, Phase 4 1, Phase 3 7, Phase 2 13, Phase 1/2 6, Phase 1 5) 2014: 36 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 2 13, Phase 1/2 8, Phase 1 10) 2015: 62 trials (Observational 2, Not applicable 2, Phase 4 1, Phase 3 6, Phase 2 18, Phase 1/2 17, Phase 1 16) 2016: 53 trials (Observational 2, Not applicable 4, Phase 3 8, Phase 2 13, Phase 1/2 10, Phase 1 16) 2017: 66 trials (Observational 4, Not applicable 4, Phase 3 6, Phase 2/3 1, Phase 2 16, Phase 1/2 12, Phase 1 23) 2018: 79 trials (Observational 3, Not applicable 4, Phase 3 9, Phase 2 20, Phase 1/2 14, Phase 1 29) 2019: 104 trials (Observational 12, Not applicable 6, Phase 3 7, Phase 2 20, Phase 1/2 23, Phase 1 36) 2020: 88 trials (Observational 6, Not applicable 2, Phase 4 1, Phase 3 11, Phase 2/3 2, Phase 2 12, Phase 1/2 26, Phase 1 28) 2021: 99 trials (Observational 10, Not applicable 4, Phase 4 1, Phase 3 8, Phase 2/3 2, Phase 2 25, Phase 1/2 24, Phase 1 25) 2022: 113 trials (Observational 5, Not applicable 6, Phase 4 1, Phase 3 9, Phase 2/3 3, Phase 2 22, Phase 1/2 24, Phase 1 43) 2023: 101 trials (Observational 11, Not applicable 10, Phase 3 5, Phase 2/3 3, Phase 2 15, Phase 1/2 15, Phase 1 42) 2024: 169 trials (Observational 23, Not applicable 15, Phase 4 1, Phase 3 12, Phase 2/3 2, Phase 2 39, Phase 1/2 33, Phase 1 44) 2025: 131 trials (Observational 19, Not applicable 9, Phase 3 9, Phase 2 31, Phase 1/2 22, Phase 1 41)

Trials that list this site and are registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 80
2025 131
2024 169
2023 101
2022 113
2021 99
2020 88
2019 104
2018 79
2017 66

Showing 10 of 30 years.

Start your 14-day trial Email me all 30 years as a PDF

2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here

Recent trials

The newest registered trials that list this site. Each title opens its ClinicalTrials.gov record.

Showing 5 of 1,533 trials.

Start your 14-day trial Email me the first 50 trials as a PDF

Source: ClinicalTrials.gov

Lead sponsors

Most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Showing 5 of 535 lead sponsors.

Start your 14-day trial Email me the first 50 lead sponsors as a PDF

Conditions studied

The specific conditions of the trials that list this site, most trials first.

Showing 5 of 330 conditions.

Start your 14-day trial Email me the first 50 conditions as a PDF